Company news
Aytu Biopharma, Inc. (NASDAQ:AYTU) news
Aytu Biopharma, Inc. news releases on 6ix. Latest, Sep 22, 2026: Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial…
Press releases & updates
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
September 22, 2026
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
September 16, 2026
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
May 31, 2026
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 18, 2026
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
May 13, 2026
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
May 6, 2026
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
February 3, 2026
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
January 27, 2026
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
January 20, 2026
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
January 20, 2026
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
January 13, 2026
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
January 12, 2026
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
December 18, 2025
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
December 15, 2025
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
November 24, 2025
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
November 13, 2025
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
November 5, 2025
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
October 28, 2025
Aytu BioPharma to Present at Upcoming October 2025 Conferences
October 10, 2025
Aytu BioPharma to Present at Upcoming September 2025 Conferences
September 24, 2025
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
September 23, 2025
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
September 16, 2025
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
June 25, 2025
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
June 22, 2025
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
June 9, 2025
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
June 6, 2025
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
June 6, 2025
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
May 14, 2025
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
May 7, 2025
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
February 11, 2025
TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. (“AYTU” OR THE “COMPANY”) AS OF OCTOBER 9, 2024 (THE “RECORD DATE”) (“CURRENT AYTU SHAREHOLDERS”) Form 8 K
December 4, 2024
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
November 12, 2024
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada
October 2, 2024
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
September 30, 2024
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
September 25, 2024
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
August 5, 2024
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
June 17, 2024
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
May 14, 2024
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
April 2, 2024
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
February 13, 2024
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
February 6, 2024
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
November 13, 2023
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
November 6, 2023
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
October 25, 2023
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
September 20, 2023
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
July 30, 2023
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
July 9, 2023
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
June 12, 2023
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
June 8, 2023